Charles River Laboratories Intl (CRL) 86.13 $CRL Charles

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Charles River Laboratories Intl (CRL) 86.13 $CRL

Charles River Laboratories Schedules Second-Quarter 2016 Earnings Release and Conference Call
BusinessWire - Mon Jul 11, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2016 financial results on Wednesday, August 3rd before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 3rd, at 8:30 a.m. ET.
CRL: 86.13 (+0.58)

5 Stocks to Buy on Stronger GDP Data
Swarup Gupta - Zacks Investment Research - Wed Jun 29, 9:34AM CDT
The most significant upward revisions which stand out are the extent of spending on software, research and development.
SNCR: 35.59 (+1.34), VRNS: 24.93 (+0.02), LH: 136.54 (+0.99), BRKR: 24.92 (+0.57), CRL: 86.13 (+0.58)

Charles River Laboratories Acquires Blue Stream Laboratories
BusinessWire - Mon Jun 27, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired Blue Stream Laboratories, Inc. Combining Blue Stream with Charles River's existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.
CRL: 86.13 (+0.58)

Charles River Laboratories to Present at Jefferies and William Blair Conferences
BusinessWire - Mon Jun 06, 7:30AM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York on Wednesday, June 8th, at 10:00 a.m. EDT, and the William Blair 36th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 14th, at 1:30 p.m. CDT (2:30 p.m. EDT). Management will present an overview of Charles River's strategic focus and business developments.
CRL: 86.13 (+0.58)

Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale Moderna's Nonclinical Development Efforts for Novel mRNA Therapeutics
BusinessWire - Mon Jun 06, 7:00AM CDT
Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics(TM) and Charles River Laboratories International, Inc. (NYSE:CRL), a leading early-stage contract research organization (CRO), today announced a strategic collaboration to support Moderna's nonclinical discovery and development efforts. Charles River will be a key partner as Moderna continues to grow and advance its pipeline spanning multiple drug modalities and therapeutic areas, conducting nonclinical activities to progress development candidates through investigational new drug (IND)-enabling studies and into the clinic.
CRL: 86.13 (+0.58)

Charles River beats Street 1Q forecasts
Automated Insights - Wed May 04, 6:20AM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported first-quarter earnings of $37.1 million.
CRL: 86.13 (+0.58)

Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations
BusinessWire - Wed May 04, 6:00AM CDT
--- First-Quarter GAAP Earnings per Share of $0.78and Non-GAAP Earnings per Share of $0.98 -
CRL: 86.13 (+0.58)

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:30AM CDT
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
AIRM: 38.48 (+0.15), PRXL: 66.78 (+0.62), EBS: 31.34 (+0.87), CRL: 86.13 (+0.58), MOH: 51.22 (+0.32)

5 Stocks to Invest on Healthcare Rebound
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:42AM CDT
Healthcare stocks bounced back this month after being mostly out of favor during the first quarter.
AIRM: 38.48 (+0.15), PRXL: 66.78 (+0.62), EBS: 31.34 (+0.87), CRL: 86.13 (+0.58), MOH: 51.22 (+0.32)

Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call
BusinessWire - Thu Apr 07, 3:30PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2016 financial results on Wednesday, May 4th before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 4th, at 8:30 a.m. ET.
CRL: 86.13 (+0.58)

CRL November 18th Options Begin Trading
DividendChannel.com - Mon Mar 21, 10:05AM CDT
Investors in Charles River Laboratories International Inc. saw new options begin trading today, for the November 18th expiration.
CRL: 86.13 (+0.58)

Charles River Laboratories to Present at Raymond James Conference
BusinessWire - Mon Mar 07, 7:30AM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 37th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 8th, at 10:25 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments.
CRL: 86.13 (+0.58)

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2015 Results from Continuing Operations and Provides 2016 Guidance
BusinessWire - Wed Feb 10, 6:00AM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.69 and Non-GAAP Earnings per Share of $1.00 -
CRL: 86.13 (+0.58)

PAREXEL International Q2 Earnings Beat, FY16 View Slashed
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 8:00AM CST
PAREXEL International Corp (PRXL) reported adjusted earnings of 90 cents per share in the second quarter of fiscal 2016, beating the Zacks Consensus Estimate by 19 cents.
PRXL: 66.78 (+0.62), INCR: 40.69 (+0.42), AHS: 43.12 (-0.02), CRL: 86.13 (+0.58)

Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 8:30AM CST
Zacks Investment Ideas feature highlights: AMN Healthcare Services, Charles River Lab, Healthways, INC Research and Air Methods
AIRM: 38.48 (+0.15), INCR: 40.69 (+0.42), HWAY: 12.23 (+0.20), AHS: 43.12 (-0.02), CRL: 86.13 (+0.58)

Top Healthcare Stocks
Brian Bolan - ZACKS - Thu Jan 21, 2:17PM CST
Top Healthcare Stocks
AIRM: 38.48 (+0.15), HWAY: 12.23 (+0.20), INCR: 40.69 (+0.42), AHS: 43.12 (-0.02), CRL: 86.13 (+0.58)

Charles River Laboratories Schedules Fourth-Quarter 2015 Earnings and 2016 Guidance Release and Conference Call
BusinessWire - Wed Jan 20, 3:30PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2015 financial results and provide 2016 guidance on Wednesday, February 10th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 10th, at 8:30 a.m. ET.
CRL: 86.13 (+0.58)

New Strong Buy Stocks for January 19th
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
CNC: 72.28 (+0.68), CBG: 27.51 (+0.84), AAL: 33.89 (+2.73), CRL: 86.13 (+0.58), CAFD: 15.89 (+0.13)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading